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ABSTRACT: Structure-based drug design can potentially
accelerate the development of new therapeutics. In this study,
a cocrystal structure of the acetylcholine binding protein
(AChBP) from Capitella teleta (Ct) in complex with a
cyclopropane-containing selective α4β2-nicotinic acetylcholine
receptor (nAChR) partial agonist (compound 5) was acquired.
The structural determinants required for ligand binding
obtained from this AChBP X-ray structure were used to refine
a previous model of the human α4β2-nAChR, thus possibly
providing a better understanding of the structure of the human
receptor. To validate the potential application of the structure of
the Ct-AChBP in the engineering of new α4β2-nAChR ligands,
homology modeling methods, combined with in silico ADME calculations, were used to design analogues of compound 5. The
most promising compound, 12, exhibited an improved metabolic stability in comparison to the parent compound 5 while
retaining favorable pharmacological parameters together with appropriate behavioral end points in the rodent studies.
■ INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) belong to the Cys-
loop superfamily of ligand-gated ion channels (LGICs) that
also include 5-HT3, GABAA/C, and glycine receptors.
1 They are
widely distributed in the central and peripheral nervous
systems, where they broadly participate in regulating major
physiological functions and pathophysiological processes
associated with learning and memory, mood, reward, motor
control, arousal, analgesia, and inflammation.2,3 Mammalian
neuronal nAChRs are homo- or heteromeric pentamers
assembled from diverse combinations of subunits (α2−α10
and β2−β4). The variety in subtype stoichiometries results in
neuronal nAChRs that exhibit highly variable properties in
regard to ligand pharmacology, activation and desensitization
kinetics, cation permeability, and subcellular and regional
distribution. Each nAChR subunit consists of a large amino-
terminal extracellular domain (ECD), a transmembrane domain
comprising four α-helices (M1−M4), and a variable cytoplas-
mic domain between M3 and M4. Acetylcholine (ACh) binding
sites are thought to be formed between the subunit interfaces of
the ECD that involve so-called loops A−C on the principal face
of an α-type subunit and the adjacent complementary face of
the neighboring subunit involving loops D−F. Known
heteromeric pentamers have a minimum of two α-type
subunits, whereas homopentamers have five, resulting in two
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to five ACh-binding sites within the ECD, the occupancy of
which by ACh or other agonists leads to global allosteric
transitions of the receptor protein that mediate channel
opening.4 The diversity of nAChR subtypes and their putative
distinctive roles in different functions provides an opportunity,
in principle, to produce subtype-specific ligands that may serve
to treat a variety of conditions. However, to date, the high
sequence homology across individual subtypes provides a
substantial challenge for the development of subtype-selective
nicotinic drugs. Nicotinic ligands lacking sufficient subtype
selectivity may cause adverse side effects. For instance, nicotine
(1) has well-known and epibatidine (2) has potential
therapeutic benefits for a number of nervous system disorders
(Figure 1). However, the therapeutic potential of these two
natural products is compromised by their unacceptable side
effects arising from their affinity to almost all subtypes of
nAChRs, albeit with different potencies. Furthermore, although
varenicline (3) has been launched and marketed as an α4β2-
nAChR partial agonist for the indication of tobacco addiction,
peripheral and central side effects, such as nausea, gastro-
intestinal symptoms, and changes in mood, have been observed
in some patients.4,5 Compound 3 also functions as a full agonist
at α7- and α3β4*-nAChRs (the asterisk denotes the possible
integration of other subunits into the pentamer) and also as a 5-
HT3 agonist.
6
Thus, understanding the detailed atomic structure remains
crucial to the design of novel nicotinic agents with minimum
side effects that selectively target designated receptor subtypes
and thus the related nervous system pathologies to which they
are linked. High-resolution crystal structures of integral
membrane protein mammalian nAChRs are not yet available.
Nevertheless, the invertebrate pentameric acetylcholine binding
proteins (AChBPs), which are structural and functional
surrogates for the N-terminal, extracellular ligand-binding
domain (LBD) of nAChRs, are more readily crystallized, and
they provide well-studied structural models that provide
insights into ligand recognition sites and other elements of
nAChR ECDs.7,8 To date, AChBPs from several different snail
species have been identified, and more than 50 different ligand-
bound cocrystal structures have been determined, facilitating
both mechanistic studies and nicotinic drug development. The
majority of these structures have been obtained with AChBP
from Aplysia californica (Ac) or Lymnaea stagnalis (Ls), which
exhibit substantial differences in affinities for nicotinic ligands
and thereby mimic distinct subtypes of nAChR.9,10 Recently, a
novel AChBP has been identified from the marine annelid
Capitella teleta (Ct), which more closely mimics α4β2-nAChRs
and their high-affinity binding of several ligands, including
compound 3, thus providing a potentially useful model to study
structural determinants of ligand recognition at this receptor
subtype.11,12
Accumulating evidence suggests that drugs targeting α4β2*-
nAChRs, which are the predominant subtype of neuronal
nAChRs, may prove to be useful in the management of major
depression.13,14 In pursuit of antidepressants that exhibit fewer
side effects and act pharmacologically in novel ways, we
recently reported the introduction of a chiral cyclopropane ring
in place of the acetylene bond in sazetidine-A (4) that furnished
a series of cyclopropane-containing ligands selective for α4β2-
nAChRs.15,16 Their superior subtype selectivity makes these
compounds stand out among all of the other α4β2-nAChR
agonists reported to date, including the marketed drug 3. One
of the most promising compounds, 5, displays subnanomolar
binding affinity at α4β2-nAChRs and excellent subtype
selectivity over α3β4*- and α7-nAChRs while acting as a
potent α4β2-nAChR partial agonist. Its favorable antidepres-
sant-like effect was demonstrated in the mouse forced-swim
test, suggesting that compound 5 represents a promising lead
for the treatment of depression and a good progenitor to other
potential candidates to advance through the drug discovery
pipeline. To provide insight into the structural determinants of
compound 5 that confer its remarkable nAChR subtype
selectivity, partial agonism, and antidepressant-like properties,
both structural studies and the comprehensive pharmacological
analysis of compound 5 were carried out.
■ RESULTS AND DISCUSSION
First, we determined binding affinities (Ki) of selected
cyclopropane ligands for Ac- and Ct-AChBP using [3H]-
epibatidine binding competition assays to evaluate the validity
of using these proteins as models for high-affinity binding at
α4β2-nAChRs. These binding data (Table 1) reveal high
affinities of the two cyclopropane ligands for the Ct-AChBP,
which are approximately 80-fold higher than those for the Ac-
AChBP. Moreover, the Ki values of compound 5 are about 2-
fold lower than those of compound 6 for both Ac- and Ct-
AChBP, which is in agreement with the previously observed
binding data16 for these two compounds at heterologously
expressed α4β2-nAChRs or rat forebrain α4β2*-nAChRs.
Taken together, these data demonstrate that compounds 5
and 6 bind with higher affinity to Ct-AChBP than to Ac-
AChBP, indicating that Ct-AChBP is more suitable for
structural studies of ligand recognition using X-ray crystallog-
raphy.
The X-ray crystal structure of Ct-AChBP in complex with
compound 5 (Figure 2) was determined at a resolution of 2.3 Å
(Supporting Information, Table S1). Figure 2a shows a cartoon
representation of Ct-AChBP along the 5-fold symmetry axis
with the C-terminus of the protein pointing toward the viewer.
Figure 1. Selected examples of nAChR ligands.
Table 1. Ligand Dissociation Constants (Ki, nM) for Ac- and
Ct-AChBPa
ligand Ac-AChBP Ct-AChBP α4β2 α4β2*
5 979 ± 364 12.8 ± 0.4 0.1 0.5
6 1927 ± 458 22 ± 3 0.6 1.7
1 598 ± 108 496 ± 30 4.9 9.8
aFor experimental procedures see the Supporting Information. The
binding data for compounds 1, 5, and 6 at α4β2- and α4β2*-nAChRs
were obtained from ref 16. α4β2*-nAChRs were prepared from rat
forebrain.
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Difference electron density in all five ligand binding sites of the
pentamer unambiguously revealed the occupancy of compound
5 (shown in sphere representation in Figure 2a). Figure 2b
shows a magnified stereoview of compound 5 as well as two
interacting water molecules (w1 and w2) built into 2Fo−Fc
electron density (gray mesh, contoured at 1.2σ). Similar to
other nicotinic ligands, compound 5 is bound at the interface
between two subunits, where it forms interactions with amino
acids of loops A, B, and C on the principal subunit and loops D,
E, and F on the complementary subunit (in Figure 2c, principal
and complementary subunits are shown in white and blue,
respectively). The azetidinyl moiety of the compound (shown
in yellow) protrudes deep inside the binding pocket, whereas
the hydroxyethyl group attached to the cyclopropane ring
points outward. The nitrogen atom of the azetidinyl moiety
forms hydrogen bonds with the carbonyl oxygen of W153
(loop B) and an ordered water molecule (w2), which forms
part of a chain of water molecules (w2−w5) extending into the
core of the β-sandwich. In addition, the azetidinyl nitrogen
forms cation−π interactions with W153 (loop B) and Y201
(loop C). Hydrophobic interactions are formed with the side
chains of V154 (loop B) and Y194, Y201 (loop C) and the
vicinal disulfide bond between C196 and C197 (loop C). The
nitrogen atom of the pyridine ring is involved in a hydrogen
bond with a water molecule (w1), which forms a bridge to
interact with the peptide backbone atoms of Q116 and I128
(loop E) on the complementary face of the binding pocket.
Hydrophobic interactions are formed with the side chains of
I118 and F128 (loop E). These interactions are remarkably
similar to those observed in the structure of Ct-AChBP in
complex with compound 3 (Figure 2d), which also binds with
high affinity to Ct-AChBP and acts as a partial agonist at the
α4β2-nAChRs.12 In the compound 3-bound structure, the
ligand interactions also include water molecules that occupy
nearly identical positions and bridge interactions within the
complementary (w1) and principal (w2−w5) binding sites
(Figure 2d). In addition, compounds 3 and 5 stabilize loop C in
similarly identical conformation, which is intermediate between
the contracted and extended conformation observed with most
agonists and antagonists, respectively.17 A notable difference
between the two structures is the different side-chain
orientation of F102 (loop A), namely, a g- versus t-rotamer
in the compound 5- and compound 3-bound structures,
respectively. Such rotamer differences of the loop A aromatic
residue have also been observed in crystal structures of Ac-
AChBP (Y91) and Ls-AChBP (Y89).18 Remarkably, a super-
position of the compound 3- and compound 5-bound
structures (Figure 2e) demonstrates that both ligands adopt
overlapping binding poses and that the two nitrogen atoms
involved in water molecule interactions (w1 and w2,
respectively) are in nearly identical locations. This result
indicates that compounds with distinct chemical structures can
Figure 2. X-ray crystal structure of the Ct-AChBP in complex with compound 5 or 3: (a) crystal structure of Ct-AChBP in complex with compound
5 as observed along the 5-fold symmetry axis; (b) stereographic view of compound 5 based on its 2Fo−Fc electron density contour at a 1.2σ level; (c)
Ct-AChBP amino acid interactions with compound 5; (d) Ct-AChBP amino acid interactions with compound 3; (e) superposition of bound
compounds 3 (orange) and 5 (yellow). Carbon = yellow, oxygen = red, nitrogen = blue, sulfur = green in all structures.
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engage in similar interactions, which critically rely on the
presence of two cationic centers spaced ∼5.8 Å from each other
(cationic centers are indicated with arrows in Figure 2e).
Together, the results from our Ct-AChBP crystal structures
reveal a common mode of interaction for compounds 5 and 3,
which both act as partial agonists at α4β2-nAChRs.
With the resolved Ct-AChBP structure in hand, and given
the greater similarity between human receptor and Ct-AChBP
binding data, a computational study was undertaken to generate
a Ct-AChBP-based homology model for the ligand binding
domain of the human α4β2-nAChR. The use of the Ct-AChBP
structure as the template is also justified by its high homology
with the human α4β2 receptor (as computed by ClustalX: α4/
Ct-AChBP = 64.6% and β2/Ct-AChBP = 62.1%) as well as by
the acceptable conservation of the key residues involved in
ligand recognition (Supporting Information, Figure S1). Figure
3 reveals a ribbon structure for the ECD of the modeled,
human α4β2 dimer (Figure 3A), which superimposes well on
the structure of the Ct-AChBP (Figure 3B). Each monomer
shows the typical, 10-stranded β-sandwich capped by an N-
terminal α-helix. The two modeled β-sandwich cores can be
nicely superimposed on those of Ct-AChBP, whereas some
divergence is observed in the superimposition of their
peripheral loops, likely due to differences between their
sequences and lengths.
The α4β2-nAChR ligand binding site is located at the dimer
interface and is lined by residues from loops A−C from the α4
subunit and loops D−E from the β2 subunit, including Y98
(loop A), W154 (loop B), and Y195 and Y202 (loop C) as well
as W57 (loop D) and V111 and L121 (loop E). As depicted in
Figure S1 of the Supporting Information, the key residues are
well conserved in the Ct-AChBP apart from W57, which is
replaced by I64 in the Ct-AChBP, and this induces a deeper
arrangement of the W153 side chain in the Ct-AChBP structure
compared to that of the homologue W154 residue due to
reduced steric hindrance of I64 compared to W57. As
documented by Figure S2 of the Supporting Information, the
key residues involved in ligand recognition show similar spatial
Figure 3. Homology model of the human α4β2-nAChR extracellular domain (ECD) including the ligand binding interface: (A) ribbon structure
representation colored by subunit (yellow = α4, azure = β2) for the human α4β2-nAChR ECD; (B) superimposition of the modeled structure (in
blue) with the experimental template from Ct-AChBP (in red).
Figure 4. Docking of compounds 5 and 12 at the ligand binding site of the modeled, human α4β2-nAChR extracellular domain: (A) main
interactions stabilizing the computed complex between compound 5 and the α4β2-nAChR model; (B) main interactions stabilizing the computed
complex between compound 12 and the α4β2-nAChR model. The protein backbone is colored in green for the α4 and in azure for the β2 subunit.
Oxygen = red, nitrogen = blue, sulfur = yellow, fluorine = brown in all structures.
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arrangements between Ct-AChBP and human α4β2-nAChR,
thus suggesting a generally conserved architecture of the
binding sites which reflects on superimposable poses of the
docked and resolved compound 5 (see below).
The reliability of the generated model and its interaction
properties were then analyzed by docking a set of reported
compound 4 derivatives (as compiled in the Supporting
Information, Table S2), including compound 5, which was
cocrystallized with the Ct-AChBP. The best complex obtained
for compound 5 within the binding cavity of the human α4β2
model is in encouraging agreement with the X-ray structure
(Figure 4A and Figure S2 of the Supporting Information).
Indeed, the azetidine ring protrudes deep inside the binding
pocket, where it can stabilize pivotal H-bonds with the
backbone carbonyl group of S153 and W154 (loop B). The
main difference between the computed complex and the
resolved one concerns F102 of the Ct-AChBP, which is
replaced by Y98 (loop A) in the α4β2-nAChR model, the
hydroxyl group of which is involved in a clear H-bond with the
charged nitrogen atom and may replace the ordered water
molecule (w2) as seen in the Ct-AChBP complex. Again, the
charged ring stabilizes a set of cation−π interactions (plus
various hydrophobic interactions) with the already mentioned
Y98 and W153 as well as with W57 (loop D), Y92 (loop A),
and Y195 and Y202 (loop C). The nitrogen atom of the
pyridine ring is involved in an H-bond with the backbone
atoms of L121 (loop E), and considering the distance between
them (3.3 Å), it might occur both directly and through a
bridging water as seen in the Ct-AChBP structure. Finally, the
hydroxyethyl group attached to the cyclopropane ring shows an
arrangement remarkably similar to that observed in the X-ray
complex because it points outward without stabilizing
significant polar interactions. In detail, the cyclopropane ring
elicits apolar contacts with V111, F119 (loop E), and A199
(loop C), whereas the hydroxyl group approaches loop C but
does not stabilize significant polar interactions apart from a
weak H-bond with the backbone atoms of A199. Such a pose
confirms that the region at the interface between α4 and β2
subunits can accommodate quite large moieties, and this is in
agreement with the recent human α4β2 models proposed by Li
and co-workers, who indeed postulated the existence of a
negative allosteric site in this region.19
When analyzing the best complexes as generated for the set
of docked compound 4 congeners, one may note that most
compounds assume a binding mode superimposable to that of
compound 5, because in all monitored complexes, the moieties
corresponding to the cyclopropane tail are unable to elicit
significant polar interactions with the β2 subunit and remain in
the subpocket flanked by loop C. Even the compounds bearing
large moieties (as seen for some carbamate derivatives, such as
compound 6) show similar binding modes, although these
moieties cannot be completely harbored below loop C and thus
partially protrude toward the β2 subunit without stabilizing
polar contacts. Indeed, the cyclopropane tail remains in a
region around loop C that, as evidenced by Figure S3 in the
Supporting Information for the human model, is surrounded by
apolar residues only without contacting polar residues of both
α4 and β2 subunits. This suggests that the hydroxyethyl group
attached to the cyclopropane ring can be modified by more
hydrophobic moieties without producing steric hindrance.
Rational Design and Synthesis of Fluorine-Containing
Cyclopropane nAChR Ligands. On the basis of our analysis
of the Ct-AChBP−compound 5 cocrystal structure together
with the molecular docking studies, it is apparent that no strong
hydrogen bonding interactions are observed for the hydroxyl
group at the terminus of the right-hand side chain, suggesting
that this hydroxyl group does not constitute an essential
pharmacophoric element for receptor recognition and may
therefore be further modified using other functional groups.
Moreover, the free hydroxyl group in compound 5 represents a
possible metabolic liability due to the potential for oxidation,
glucuronidation, sulfation, and other bioconjugations.20 Con-
sequently, small and hydrophobic functional groups might be
able to replace the polar and hydrophilic hydroxyl group, thus
yielding new cyclopropane ligands with improved drug-like
properties. In the field of medicinal chemistry, aside from the
introduction or presence of nitrogen atoms in the drug
scaffolds, the incorporation of fluorine atoms likely constitutes
the second most favored heteroatom that has been incorpo-
rated into biologically active molecules. The unique nature of
fluorine, including its small size, high electronegativity, and high
energy of bond formation to carbon, imparts a variety of
advantages to fluorine-containing drugs. These advantages
include properties such as enhanced binding interactions,
improved metabolic stability, lack of alkylating activity (in
contrast to chlorides or bromides), changes in physicochemical
properties, and possibly enhanced subtype selectivity. It is not
surprising that about 20% of all drugs currently on the market
contain at least one fluorine atom, with many more to
come.21,22 The length of the C−F bond (1.41 Å) is similar to
that of the C−O bond (1.43 Å), suggesting that these atoms are
bioisosteres. In addition, it is well accepted that the C−F unit
may participate in electrostatic interactions responsible for
strengthening ligand-protein binding interactions.23 With these
considerations in mind, we designed analogues of compound 5
in which the hydroxyl group is substituted with either hydrogen
or fluorine atoms (compounds 10, 12, and 13). As shown in
Table S3 of the Supporting Information, the blood−brain
barrier (BBB) permeability of these new analogues, as
estimated by their calculated logBB values, increases from
−0.5 to about −0.1, which is similar to the logBB of compound
3. Drug permeability across the BBB is, of course, essential to
obtaining therapeutic drug levels in the brain, as this is where
the targeted α4β2-nAChRs are expressed.24 These numbers
suggest a beneficial effect of the replacement of the hydroxyl
group with either hydrogen or fluorine atoms on BBB
penetration and subsequent bioavailability.
Docking simulations of the three proposed compounds
confirm the reliability of such modifications because all
derivatives assume poses almost superimposable to that of
compound 5 and stabilize reinforced hydrophobic interactions
with the region surrounding loop C. Thus, Figure 4B illustrates
the best complex for compound 12, showing that it stabilizes
the same interaction pattern already observed for compound 5
involving the azetidine and the pyridine rings. Notably, Figure
4B shows that the fluorine atom is inserted in a markedly
hydrophobic niche lined by V111, F119, and the characteristic
disulfide bridge of loop C (C197−C198), thus confirming the
relevance of the apolar contacts elicited by this moiety.
The synthesis of compounds 10, 12, and 13 is described in
Scheme 1. For the terminal methyl compound, the optically
pure alcohol 716 was acylated with isobutyric anhydride and the
benzyl group was removed by hydrogenolysis, followed by
installation of the azetidine moiety by a modified Mitsunobu
reaction to obtain the intermediate 8. After removal of the
isobutyryl group, the alcohol intermediate was subjected to
Journal of Medicinal Chemistry Article
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standard Swern oxidation and Wittig reaction to furnish the
olefin 9. Successive hydrogenation of the terminal double bond
and removal of the Boc group smoothly gave the target
compound 10 as its trifluoroacetate salt. For the fluorine-
containing analogues, the starting alcohol 1116 was tosylated
followed by reaction with n-tetrabutylammonium fluoride. Boc
deprotection of the resulting fluoride yielded compound 12 as
its trifluoroacetate salt. Similarly, the aldehyde prepared from
the same alcohol 11 by Swern oxidation was converted to gem-
difluoride using the stable and mild reagent (diethylamino)-
difluorosulfonium tetrafluoroborate (XtalFluor-E), in conjunc-
tion with Et3N·3HF as a promoter.
25 After removal of the Boc
group, the resulting gem-difluoride 13 was obtained as its
trifluoroacetate salt.
In Vitro Radioligand Binding and Functional Studies.
The Ki values of all of the synthesized cyclopropane
compounds, 10, 12, and 13, were evaluated by [3H]epibatidine
binding competition assays at seven heterologously expressed
rat nAChR subtypes. As shown in Table 2, compounds 10, 12,
and 13 exhibited subnanomolar to low nanomolar binding
affinities for both the α4β2- and α4β2*-nAChRs, which are
comparable to those of compound 5. This confirms that the
interactions elicited by the cyclopropyl tail are restricted to
apolar contacts only and that the hydroxyl group does not take
part in the binding process. All three of these compounds
demonstrated good selectivity for nAChRs containing β2
subunits (α2β2-, α3β2-, α4β2-, and α4β2*-nAChRs) over β4
subunits (α3β4-, α2β4-, and α4β4-nAChRs). As it is known
that α3β4*-nAChRs mediate autonomic nicotinic signaling,
interaction with these receptors is likely to contribute to
adverse side effects.1,26 With the exception of compound 10,
the selectivity for α4β2- over α3β4-nAChRs of compounds 12
and 13 is >16000-fold, suggesting that few if any peripheral side
effects should be observed.
Next, the functional activity of compounds 10, 12, and 13 at
the human α4β2-, α3β4*-, and α1β1γδ-nAChRs was
determined using the 86Rb+ ion flux assays and SH-EP1, SH-
SY5Y, and TE671/RD cells, respectively (Table 3; Supporting
Information, Figure S4).27−30 All three of these ligands were
found to be highly potent, partial agonists at the mixture of high
sensitivity (HS) and low sensitivity (LS) α4β2-nAChRs having
weak if any agonist activity at α3β4*- or α1β1γδ-nAChRs
(Supporting Information, Figure S4). Their efficacies ranged
from 68 to 76% of the response to a maximally efficacious
concentration of the full agonist, carbamylcholine, for actions at
HS α4β2-nAChRs. At LS α4β2-nAChRs, these ligands had no
measurable efficacy as agonists. Their inactivation of nAChR
function (following 10 min of pre-exposure; blockade of
carbamylcholine stimulation) was most potent for α4β2-
nAChRs and weak or absent out to 3 μM for actions at
α3β4*- or α1β1γδ-nAChRs, respectively. Consistent with the
binding data, the fluorine-containing compounds 12 and 13
were about 2-fold more potent than compound 10, in both
agonism and functional inactivation at α4β2-nAChRs, which is
similar to that seen for parent compound 5. The absence or
weakness of agonist or antagonist activity at ganglionic α3β4*-
or muscle-type α1β1γδ-nAChRs indicates that the occurrence
of peripheral side effects is unlikely. When all of the present
data are taken into account, the presence of a fluorine at the
terminus of the side chain appendage leads to a compound with
an improved pharmacological profile compared to a hydrogen
atom, as not only is high affinity for α4β2-nAChRs maintained
but so is the excellent selectivity over α3β4*-nAChRs.
Behavioral Pharmacology and Metabolic Stability
Test. To acquire a preliminary in vivo evaluation of our
nicotinic ligands for behavioral effects relevant to psychiatric
disease, we used SmartCube,31 an automated system in which
behaviors of compound-treated mice are captured by digital
video and analyzed with computer algorithms. We compared
the behavioral signature of a test compound to a database of
behavioral signatures obtained using a large set of diverse
reference compounds. In this way, the neuropharmacological
effects of a test compound can be predicted by similarity to
major classes of compounds, such as antipsychotics, anxiolytics,
and antidepressants. As shown in Figure 5, all of the selected
nicotinic ligands produced, in most cases, dose-dependent
Scheme 1. Synthesis of Compounds 10, 12, and 13a
aConditions: (a) isobutyric anhydride, cat. DMAP, Et3N, CH2Cl2, 0
°C to rt; (b) 10% Pd/C, H2, EtOAc/MeOH, rt; (c) 1-(tert-
butoxycarbonyl)-(2S)-azetidinylmethanol, azodicarbonyldipiperidide
(ADDP), P(n-Bu)3, PhMe, 0 °C to rt; (d) NaOMe, MeOH, 40 °C;
(e) (i) (COCl)2, DMSO, Et3N, CH2Cl2, −78 °C; (ii) Ph3PCH2,
THF, 0 °C; (f) CF3COOH, CH2Cl2, rt; (g) (i) TsCl, Et3N, CH2Cl2, 0
°C to rt; (ii) n-Bu4NF, THF, rt; (h) (i) (COCl)2, DMSO, Et3N,
CH2Cl2, −78 °C; (ii) XtalFluor-E, Et3N·3HF, CH2Cl2, rt.
Table 2. Binding Affinities of Cyclopropane Ligands and Nicotine at Seven nAChR Subtypesa
Ki (nM)
compd α2β2 α2β4 α3β2 α3β4 α4β2 α4β2* α4β4
5 0.1 249 3.0 6520 0.1 0.5 82.6
10 0.4 41.8 ± 9 10.3 ± 1.8 852.1 0.4 ± 0.1 1.2 ± 0.2 14.8 ± 2.8
12 0.4 ± 0.1 137.6 6.1 ± 1.9 3224 0.2 0.9 ± 0.1 39.1 ± 5.6
13 0.3 ± 0.1 85.4 ± 15.1 6.9 ± 1 1976 0.1 0.8 ± 0.2 23 ± 3.1
1 5.5 70 29 260 4.9 9.8 23
aFor experimental procedures see PDSP Assay Protocol Book (http://pdsp.med.unc.edu/). α4β2*-nAChRs were prepared from rat forebrain. The
binding data for compounds 1 and 5 were obtained from ref 16. SEM values are not provided for Ki values >100 nM.
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behavioral signatures that are quite different from those of the
vehicle and contained an antidepressant−anxiolytic component
and other therapeutic signatures. All of the compounds showed
no or only a minor profile of side effects.
Next, the antidepressant-like properties of compounds 10,
12, and 13 were further demonstrated in the classical mouse
forced-swim test,32 an assay in which mice are placed into a
beaker of water and the time the mouse spends passively
floating in the water (immobility) is recorded. Most traditional
antidepressants decrease the amount of time the mouse spends
immobile. Mice were administered compound 10, 12, or 13 or
the selective serotonin reuptake inhibitor sertraline, as a
positive control (20 mg/kg). Compounds 10 and 13, the
least potent and the most potent ligands in vitro, respectively,
had no significant effect in the forced-swim test when
administered intraperitoneally at a dose of 3 or 10 mg/kg. In
contrast, compound 12 exhibited an antidepressant-like effect
when administered intraperitoneally or orally, with a significant
reduction in immobility at the minimal dose of 3 mg/kg
(Figure 6).
Additionally, we note that the carbamate derivative 6
reported in our previous publication16 was metabolically
more stable than the hydroxyl compound 5 in the microsomal
stability assays (98 vs 80% of the tested compound remained
unchanged after 1 h of incubation with a starting concentration
of 1 μM). In this context, the fluorinated compound 12 is likely
to possess enhanced metabolic stability compared to the
hydroxyl compound 5, as the hydroxyl group of the latter
compound is likely to undergo oxidation and/or bioconjugation
reactions.33 Incubation with mouse, rat, dog, and human liver
microsomes34 demonstrated that no less than 98% of
compound 12 remained unchanged after 1 h of incubation at
Table 3. Potencies and Efficacies of Ligand Agonism and Inactivation at α4β2-nAChRsa
agonism inactivation
compd EC50 (nM) efficacy at HS (%) Hill slope IC50 (nM) efficacy (%) Hill slope
5 10.2 ×/÷ 1.7 92 ± 6 1.0 ± 0.4 9.4 ×/÷ 1.1 62 ± 1 −1.4 ± 0.2
10 19.1 ×/÷ 1.2 68 ± 4 1.1 ± 0.2 22.2 ×/÷ 1.4 87 ± 4 −1.1 ± 0.3
12 11.3 ×/÷ 1.4 76 ± 6 1.3 ± 0.5 10.2 ×/÷ 1.3 81 ± 4 −1.2 ± 0.4
13 8.8 ×/÷ 1.2 75 ± 7 1.4 ± 0.4 8.6 ×/÷ 1.3 86 ± 4 −1.1 ± 0.3
1 290 ×/÷ 1.1 88 ± 2b 1.0 ± 0.1 430 ×/÷ 1.1 92 ± 2 −0.8 ± 0.09
aFor experimental procedures see ref 16. Potencies (EC50 or IC50 values) and inactivation efficacies were measured for actions at a mixture of high-
sensitivity (HS) and low-sensitivity (LS) α4β2-nAChRs. Due to the semilogarithmic nonlinear regression analysis, the SEM for EC50 or IC50 values is
not symmetric in linear space. EC50 or IC50 values are therefore reported with a multiplying/dividing factor. Agonism efficacy values were
extrapolated using sazetidine-A defined as a full agonist at the HS α4β2-nAChR (see the Supporting Information for details). Results for compounds
1 and 5 were obtained from ref 16. bThe efficacy of agonism for compound 1 was available only for a mixed population of HS and LS α4β2-nAChRs.
The efficacy of agonism for all other compounds at LS α4β2-nAChRs was approximately zero.
Figure 5. All of the cyclopropane-containing α4β2-nAChRs partial agonists 5, 6, 10, 12, and 13 produced a signature of activity suggesting a
potential antidepressant-like effect. The drug was injected ip, 15 min before testing.
Figure 6. Mouse forced-swim data for compound 12. The selective serotonin re-uptake inhibitor, sertraline, produced the expected decrease in
immobility. (ANOVAs: F (3,36) = 12.38, p < 0.001 (left); F (4,44) = 38.97, p < 0.001 (right). (∗) Fisher’s PLSD post hoc test: ps < 0.05 vs vehicle.)
n = 910/group.
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a starting concentration of 2 μM, thereby supporting the
greater metabolic stability of the fluorinated compound 12
relative to its parent compound 5.
■ CONCLUSIONS
Herein we have used the X-ray structure of the α4β2-nAChR
partial agonist 5 in complex with Ct-AChBP to refine our
homology model of the human α4β2-nAChR. By combining
homology modeling methods with in silico ADME calculations,
we in turn designed and synthesized several new analogues of
compound 5. The in vitro binding and functional data as well as
the in vivo behavioral efficacy obtained for the fluorinated
compound 12 were found to be comparable to the same
parameters obtained for the parent hydroxyl-containing
compound 5. Additionally, as expected on the basis of the
time-tested principles of medicinal chemistry, the metabolic
stability of analogue 12 is better than that of 5. The more
limited metabolic stability of 5, which is subject to both
oxidation and bioconjugation reactions, conspires to make this
compound a suboptimal drug-like molecule. Of greatest
significance is the structural information gleaned from the
cocrystal structure of compound 5 in complex with Ct-AChBP.
This particular structure has enabled us to refine our homology
model of the human α4β2-nAChR, and as such we anticipate
that we will be able to design other chemical scaffolds with
which to interrogate these important brain receptors, thus
providing the opportunity to create improved therapeutics for a
host of pathophysiological mechanisms.
■ EXPERIMENTAL SECTION
General Procedures for SmartCube. Drugs were injected 15
min before the test, during which multiple challenges were presented
over the course of the test session. At least 12 mice were used in each
treatment group. Digital videos of the subjects were processed with
computer vision algorithms to extract over 2000 dependent measures
including frequency and duration of behavioral states such as
grooming and rearing and many other features obtained during the
test session. These data were compared against a standard database of
therapeutic class signatures obtained with the same experimental
protocol. The database comprises 14 classes of drugs with some of the
major classes, such as the antidepressant class, comprising several
subclasses with representatives of most of the drugs on the market.
Using machine learning techniques, the reference database was
combed to find reference drug class signatures. The best performing
techniques were chosen from our evaluation tests and used to build
classifiers that capture the therapeutic class signatures. The behavioral
signatures of the test compound were then assessed quantitatively with
these classifiers to predict total and specific potential therapeutic
utility.31,35 We present the major signatures in four general groups:
antidepressants and anxiolytics, other therapeutics effects, side effects
and signatures not recognized by the classifiers, and similarity to
vehicle (inactivity).
General Chemistry. All chemicals were purchased from Sigma-
Aldrich or Chem-Impex, and solvents were used as obtained from
Fisher Scientific or Sigma-Aldrich without further purification.
Anhydrous THF and CH2Cl2 were obtained by distillation over
sodium wire or CaH2, respectively. All nonaqueous reactions were run
under an argon atmosphere with exclusion of moisture from reagents,
and all reaction vessels were oven-dried. The progress of reactions was
monitored by TLC on SiO2. Spots were visualized by their quenching
of the fluorescence of an indicator admixed to the SiO2 layer or by
dipping into I2/SiO2 mixture. Products were purified by column
chromatography on 230−400 mesh SiO2. Proton and carbon NMR
spectra were recorded at spectrometer frequencies of 400 and 100
MHz, respectively. NMR chemical shifts were reported in δ (ppm)
using the δ 7.26 signal of CHCl3 (
1H NMR), the δ 4.80 signal of HDO
(1H NMR), and the δ 77.23 signal of CDCl3 (
13C NMR) as internal
standards. 13C NMR spectra in D2O were not adjusted. Optical
rotation was detected on an Autopol IV automatic polarimeter. Mass
spectra were measured in the ESI mode at an ionization potential of 70
eV with an LC-MS MSD (Hewlett-Packard). The final compounds
were purified by preparative HPLC, which was carried out on an ACE
5 AQ column (150 × 20 mm), with detection at 254 and 280 nm on a
Shimadzu SPD-10A VP detector, flow rate =17.0 mL/min, with a
gradient of 0−50% methanol in water (both containing 0.05 vol % of
CF3COOH) in 30 min. Purities of final compounds (>98%) were
established by both elemental analysis and analytical HPLC, which was
carried out on an Agilent 1100 HPLC system with a Synergi 4 μm
Hydro-RP 80A column, with detection at 254 or 280 nm on a variable
wavelength detector G1314A, flow rate =1.4 mL/min, with a gradient
of 0−100% methanol in water (both containing 0.05 vol % of
CF3COOH) in 18 min.
3-[(2(S)-Azetidinyl)methoxy]-5-((1S,2S)-2-ethylcyclopropyl)-
pyridine trifluoroacetate (10): 1H NMR (D2O) δ 8.29 (s, 1H), 8.19
(s, 1H), 7.81 (s, 1H), 4.95 (m, 1H), 4.50 (d, J = 4.0 Hz, 2H), 4.17−
4.02 (m, 2H), 2.68 (q, J = 8.4 Hz, 2H), 1.88 (m, 1H), 1.48−1.35 (m,
2H), 1.25 (m, 1H), 1.08 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR
(D2O) δ 162.6 (TFA), 156.2, 147.3, 132.2, 128.2, 125.4, 116.2 (TFA),
67.5, 58.6, 43.6, 27.6, 26.3, 20.2, 19.9, 17.1, 12.4; [α]D
20 = +32.7 (c
0.22, MeOH); HPLC purity = 99.2%; tR = 11.9 min. Anal. Calcd for
C14H20N2O·2.25CF3COOH·0.4H2O: C, 44.79; H, 4.68; F, 25.85; N,
5.65. Found: C, 44.67; H, 4.53; F, 25.79; N, 5.62.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2-fluoroethyl)-
cyclopropyl]pyridine trifluoroacetate (12): 1H NMR (D2O) δ 8.32
(s, 1H), 8.22 (s, 1H), 7.85 (s, 1H), 4.95 (m, 1H), 4.66 (t, J = 6.0 Hz,
1H), 4.55−4.50 (m, 3H), 4.10 (m, 2H), 2.68 (q, J = 8.4 Hz, 2H), 1.99
(m, 1H), 1.82 (m, 2H), 1.37 (m, 1H), 1.17 (m, 2H); 13C NMR (D2O)
δ 162.1 (TFA), 155.8, 146.0, 132.0, 128.1, 125.4, 115.8 (TFA), 84.3
(d, JC−F = 157.7 Hz), 67.1, 58.2, 43.2, 33.2 (d, JC−F = 18.9 Hz), 21.1,
19.8, 19.2, 15.8; 19F NMR (D2O) δ −75.7, −217.8; [α]D20 = +33.8 (c
0.26, MeOH); HPLC purity = 99.4%; tR = 6.4 min. Anal. Calcd for
C14H19FN2O·2.0CF3COOH·0.8H2O: C, 43.87; H, 4.62; F, 26.99; N,
5.68. Found: C, 43.51; H, 4.23; F, 26.80; N, 5.58.
3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2,2-difluoroethyl)-
cyclopropyl]pyridine trifluoroacetate (13): 1H NMR (D2O) δ 8.34
(s, 1H), 8.25 (s, 1H), 7.87 (s, 1H), 6.04 (tt, JH−F = 56.4 Hz, JH−H = 4.0
Hz, 1H), 4.97 (m, 1H), 4.51 (d, J = 4.0 Hz, 2H), 4.10 (m, 2H), 2.68 (t,
JH−F = 8.4 Hz, 2H), 2.09−1.92 (m, 3H), 1.38 (m, 1H), 1.22 (m, 2H);
13C NMR (D2O) δ 162.2 (TFA), 155.9, 145.3, 132.2, 128.3, 125.7,
117.1 (t, JC−F = 235.9 Hz), 115.8 (TFA), 67.1, 58.2, 43.2, 36.5 (t, JC−F
= 20.9 Hz), 19.8, 19.0, 17.2 (t, JC−F = 7.4 Hz), 15.0;
19F NMR (D2O) δ
−75.8, −116.5; [α]D20 = +25.0 (c 0.2, MeOH); HPLC purity = 99.3%;
tR = 6.3 min. Anal. Calcd for C14H18F2N2O·2.7CF3COOH·1.2H2O: C,
38.98; H, 3.89; F, 32.10; N, 4.69. Found: C, 38.91; H, 3.58; F, 31.81;
N, 4.65.
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